US · PAHC · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Phibro Animal Health Corporation (PAHC) intrinsic value and stock valuation
$33.29as of 2026-11-21 · Mkt cap 1.46B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Phibro Animal Health Corporation DCF and intrinsic value
InvestorsCraft values PAHC with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from PAHC’s statements →
Phibro Animal Health Corporation Graham Number
Graham Number: $13.75d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Organon & Co. (OGN) $13.89
- Pediatrix Medical Group, Inc. (MD) $30.22
- Aurinia Pharmaceuticals Inc. (AUPH) $14.70
- ANI Pharmaceuticals, Inc. (ANIP) $68.55
- MannKind Corporation (MNKD) $3.85
- Alvotech (ALVO) $4.12
- Evotec SE (EVO) $1.32
- Tilray Brands, Inc. (TLRY) $1.89
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.02B | $977.9M | $942.3M | $833.4M |
| Operating income | $110.5M | $53.3M | $71.9M | $79M | $74.9M |
| Net income | $48.3M | $2.42M | $32.6M | $49.2M | $54.4M |
| EPSd | $1.19M | $59.7K | $805.2K | $1.21M | $1.34M |
| Operating cash flow | $80.1M | $87.6M | $13.3M | $31.7M | $48.3M |
| Capital expenditure | -$-38.29M | -$-41.24M | -$-51.79M | -$-37.04M | -$-29.32M |
| Free cash flow | $41.8M | $46.4M | -$-38.48M | -$-5.39M | $19M |
| Total assets | $1.36B | $982.2M | $971.4M | $931.7M | $841.3M |
| Total debt | $761.6M | $525.5M | $510M | $470.5M | $426.7M |
| Net debt | $693.5M | $454.9M | $468.7M | $396.2M | $376.5M |
| Total equity | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M |
| Cash and short-term investments | $77M | $114.6M | $81.3M | $91.3M | $93.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.02B | $977.9M | $942.3M | $833.4M |
| Cost of revenue | $896.3M | $704.6M | $679.7M | $656.9M | $562M |
| Gross profit | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $289.5M | $259.8M | $226.4M | $206.4M | $196.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $289.5M | $259.8M | $226.4M | $206.4M | $196.5M |
| Cost and expenses | $1.19B | $964.4M | $906M | $863.3M | $758.5M |
| Interest income | $2.62M | $4.47M | $3.35M | $820K | $840K |
| Interest expense | $33.3M | $22M | $18M | $12.1M | $10.4M |
| Depreciation and amortization | $45.6M | $36.2M | $34M | $32.7M | $31.9M |
| Ebitda | $146.9M | $69.1M | $106M | $117.1M | $110.2M |
| Operating income | $110.5M | $53.3M | $71.9M | $79M | $74.9M |
| Total other income/expenses, net | -$-42.47M | -$-42.4M | -$-17.78M | -$-6.66M | -$-8.4M |
| Income before tax | $68M | $10.9M | $54.1M | $72.3M | $66.5M |
| Income tax expense | $19.7M | $8.5M | $21.5M | $23.2M | $12.1M |
| Net income | $48.3M | $2.42M | $32.6M | $49.2M | $54.4M |
| Weighted average shares outstanding | $40.5M | $40.5M | $40.5M | $40.5M | $40.5M |
| Weighted average diluted shares outstanding | $40.7M | $40.5M | $40.5M | $40.5M | $40.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $77M | $114.6M | $81.3M | $91.3M | $93.2M |
| Net receivables | $228M | $169.5M | $163.5M | $166.5M | $146.9M |
| Inventory | $444.4M | $265.9M | $277.6M | $259.2M | $216.3M |
| Total current assets | $810.6M | $601M | $585.7M | $566.2M | $498.9M |
| Property, plant and equipment, net | $396M | $240.9M | $231.3M | $203.2M | $187.7M |
| Goodwill and intangible assets | $96.1M | $99.6M | $108.3M | $117.1M | $115M |
| Long-term investments | $11.7M | $11.5M | $11.1M | $10.4M | $10.1M |
| Total non-current assets | $550.3M | $381.2M | $385.7M | $365.5M | $342.4M |
| Total assets | $1.36B | $982.2M | $971.4M | $931.7M | $841.3M |
| Accounts payable | $138.2M | $85.6M | $73.9M | $95.6M | $68.4M |
| Short-term debt | $25.4M | $37.3M | $28.4M | $21.1M | $16M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $293.5M | $204.2M | $176M | $190.8M | $164.1M |
| Long-term debt | $736.2M | $488.2M | $481.6M | $449.4M | $410.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $781.8M | $521.4M | $512.9M | $478.4M | $438.7M |
| Capital lease obligations | $42.9M | $37.4M | $35.1M | $37.6M | $34.6M |
| Total liabilities | $1.08B | $725.5M | $688.9M | $669.3M | $602.8M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | $272.7M | $243.9M | $260.9M | $247.8M | $218M |
| Accumulated other comprehensive income (loss) | -$-124.02M | -$-123.53M | -$-114.21M | -$-121.11M | -$-115.29M |
| Total equity | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M |
| Total investments | $20.7M | $55.5M | $51.1M | $27.4M | $53.1M |
| Total debt | $761.6M | $525.5M | $510M | $470.5M | $426.7M |
| Net debt | $693.5M | $454.9M | $468.7M | $396.2M | $376.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $48.3M | $2.42M | $32.6M | $49.2M | $54.4M |
| Depreciation and amortization | $45.6M | $36.2M | $34M | $32.7M | $31.9M |
| Stock-based compensation | $720K | $470K | $0.00 | $0.00 | $1.13M |
| Change in working capital | -$-21.56M | $33.1M | -$-41.13M | -$-44.64M | -$-29.87M |
| Accounts receivable | -$-55.21M | -$-8.68M | $5.33M | -$-23.62M | -$-18.21M |
| Inventory | -$-44.29M | $2.64M | -$-11.22M | -$-47M | -$-12.5M |
| Accounts payable | $45.6M | $12M | -$-22.83M | $26.4M | $3.18M |
| Net cash provided by operating activities | $80.1M | $87.6M | $13.3M | $31.7M | $48.3M |
| Investments in property, plant and equipment | -$-38.29M | -$-41.24M | -$-51.79M | -$-37.04M | -$-29.32M |
| Acquisitions, net | -$-286.53M | -$-3.28M | $0.00 | -$-13.51M | $29.3M |
| Net cash used for investing activities | -$-288.69M | -$-48.19M | -$-74.02M | -$-22.58M | -$-18.58M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-19.45M | -$-19.44M | -$-19.44M | -$-19.44M | -$-19.43M |
| Net cash used for financing activities | $207.1M | -$-6.77M | $27M | $16.3M | -$-17M |
| Net change in cash | -$-2.57M | $29.3M | -$-32.97M | $24M | $13.9M |
| Cash at end of period | $68M | $70.6M | $41.3M | $74.3M | $50.2M |
| Operating cash flow | $80.1M | $87.6M | $13.3M | $31.7M | $48.3M |
| Capital expenditure | -$-38.29M | -$-41.24M | -$-51.79M | -$-37.04M | -$-29.32M |
| Free cash flow | $41.8M | $46.4M | -$-38.48M | -$-5.39M | $19M |
Line items
Line items
Line items
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
- CEO
- Daniel Bendheim
- Employees
- 2.48K
- Beta
- 0.46
Included in
Explore
Frequently asked questions
What is the intrinsic value of Phibro Animal Health Corporation (PAHC)?
Phibro Animal Health Corporation (PAHC) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PAHC undervalued?
PAHC trades at a price of $33.29 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.